Microbot Medical Inc.

NASDAQ:MBOT

Medical - Instruments & Supplies

Healthcare
$0.98 -2.93%

-$0.06 today

Market cap
$65.73M
Beta
1.04
P/E (TTM)
-8.6
EPS (TTM)
-$0.21
52W Low $1.60High $4.67

Volume 0.87M

Average 1.60M

MBOT Research & Development

Spending on developing new products, technologies, and improvements to existing offerings.

Microbot Medical Inc.NASDAQ: MBOT

Research & Development · Q1 FY2026 · quarter ended Mar 2026

Research & development declines year over year

Q1 FY2026 research & development of $1.29M fell 11.4% year over year, in line with the -11.4% change in trailing-twelve-month research & development. Sequentially, it fell 16.1% from the prior quarter. Over 3 fiscal years it compounded at -6.7% a year.

Context

  • Research & development increased in 1 of the last 3 fiscal years.

What to watch

Whether quarterly growth of -11.4% holds above the trailing-twelve-month pace of -11.4%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
$1.29M-16.1% QoQ
Last fiscal yearDec 2025
$6.28M-5.2% YoY
LTMMar 2026
$6.11M-11.4% YoY
Research & Development past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-11.4%——
1 year-5.2%——
3-year CAGR-6.7%——
5-year CAGR——
10-year CAGR——

Research & Development history

USD · from the income statement

Latest · FY2025
6.28M USD
Year-over-year change
-5.2%
4-year CAGR
+0.5%

Research & Development vs competitors

How MBOT compares with its peers on the latest reported figures

  • Peers report in different currencies, so research & development is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of -11.4% is the 8th highest of 10, against a peer median of +6.1%.
  • Research & development amounts to 5814.3% of revenue for MBOT, versus a peer median of 422.2%.
MBOT Competitors
Research & Development for MBOT and competitors
Company Period LTM YoY 3-year CAGR% of revenue
CNTXContext Therapeutics Inc.LTM Mar 2026$35.41M USD+46.4%+65.0%—
OVIDOvid Therapeutics Inc.LTM Mar 2026$30.07M USD-8.9%+1.3%422.2%
RCELAVITA Medical, Inc.LTM Mar 2026$20.18M USD-5.9%+14.6%27.9%
VANIVivani Medical, Inc.LTM Mar 2026$18.17M USD+11.9%+8.6%—
CRDLCardiol Therapeutics Inc.LTM Mar 2026CA$15.22M CAD+22.5%+0.1%—
DCGODocGo Inc.LTM Mar 2026$13.63M USD+6.1%+36.1%4.5%
CLNNClene Inc.LTM Mar 2026$12.86M USD-17.9%-24.0%9596.3%
MBOTMicrobot Medical Inc.LTM Mar 2026$6.11M USD-11.4%-6.7%5814.3%
ORMPOramed Pharmaceuticals Inc.LTM Mar 2026$5.77M USD-21.5%-38.7%—
ZTEKZentek Ltd.LTM Mar 2026CA$1.65M CAD+255.2%+0.2%995.9%
Peer median (excluding MBOT) —+6.1%+1.3%422.2%

Competitors are the stored peer set for MBOT. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue00000
Cost of Revenue00106K91K0
Gross Profit00(106K)(91K)0
Gross Margin—————
Research & Development6.15M7.74M5.72M6.63M6.28M
Selling, General & Admin5.41M5.58M4.13M5M8.25M
Operating Expenses11.36M13.28M9.75M11.53M14.74M
Depreciation & Amortization76K102K106K91K47K
EBITDA(11.24M)(13.34M)(10.63M)(11.35M)(13.1M)
EBITDA Margin—————
Operating Income(11.36M)(13.28M)(9.86M)(11.63M)(14.74M)
Operating Margin—————
Interest Income44K54K228K182K1.29M
Interest Expense00000
Other Income / Expenses44K113K(885K)182K1.6M
Income Before Tax(11.31M)(13.17M)(10.74M)(11.44M)(13.14M)
Pre-Tax Margin—————
Income Tax Expense00000
Net Income(11.31M)(13.17M)(10.74M)(11.44M)(13.14M)
Net Margin—————
EPS (Basic)(1.59)(1.81)(1.05)(0.73)(0.29)
EPS (Diluted)(1.59)(1.81)(1.05)(0.73)(0.29)
Weighted Avg Shares7.11M7.26M10.2M15.65M45.79M
Weighted Avg Shares (Diluted)7.11M7.26M10.2M15.65M45.79M

Microbot Medical Inc.

NASDAQ:MBOT

Intrinsic Alpha fair value

Locked

Current Price

$0.98

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.